Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 123

1.

Uremic Toxin Concentrations are Related to Residual Kidney Function in the Pediatric Hemodialysis Population.

Snauwaert E, Holvoet E, Van Biesen W, Raes A, Glorieux G, Vande Walle J, Roels S, Vanholder R, Askiti V, Azukaitis K, Bayazit A, Canpolat N, Fischbach M, Godefroid N, Krid S, Litwin M, Obrycki L, Paglialonga F, Ranchin B, Samaille C, Schaefer F, Schmitt CP, Spasojevic B, Stefanidis CJ, Van Dyck M, Van Hoeck K, Collard L, Eloot S, Shroff R.

Toxins (Basel). 2019 Apr 24;11(4). pii: E235. doi: 10.3390/toxins11040235.

2.

Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients.

Fourdinier O, Schepers E, Metzinger-Le Meuth V, Glorieux G, Liabeuf S, Verbeke F, Vanholder R, Brigant B, Pletinck A, Diouf M, Burtey S, Choukroun G, Massy ZA, Metzinger L; European Uremic Toxin Work Group-EUTox.

Sci Rep. 2019 Mar 14;9(1):4477. doi: 10.1038/s41598-019-41101-8.

3.

The role of the intestinal microbiota in uremic solute accumulation: a focus on sulfur compounds.

Perna AF, Glorieux G, Zacchia M, Trepiccione F, Capolongo G, Vigorito C, Anishchenko E, Ingrosso D.

J Nephrol. 2019 Jan 23. doi: 10.1007/s40620-019-00589-z. [Epub ahead of print] Review.

PMID:
30673975
4.

Evolution of protein-bound uremic toxins indoxyl sulphate and p-cresyl sulphate in acute kidney injury.

Veldeman L, Vanmassenhove J, Van Biesen W, Massy ZA, Liabeuf S, Glorieux G, Vanholder R.

Int Urol Nephrol. 2019 Feb;51(2):293-302. doi: 10.1007/s11255-018-2056-x. Epub 2019 Jan 2.

PMID:
30604232
5.

Association between Protein-Bound Uremic Toxins and Asymptomatic Cardiac Dysfunction in Patients with Chronic Kidney Disease.

Chinnappa S, Tu YK, Yeh YC, Glorieux G, Vanholder R, Mooney A.

Toxins (Basel). 2018 Dec 5;10(12). pii: E520. doi: 10.3390/toxins10120520.

6.

Gut microbiota dynamics and uraemic toxins: one size does not fit all.

Joossens M, Faust K, Gryp T, Nguyen ATL, Wang J, Eloot S, Schepers E, Dhondt A, Pletinck A, Vieira-Silva S, Falony G, Vaneechoutte M, Vanholder R, Van Biesen W, Huys GRB, Raes J, Glorieux G.

Gut. 2018 Nov 21. pii: gutjnl-2018-317561. doi: 10.1136/gutjnl-2018-317561. [Epub ahead of print] No abstract available.

7.

Gut-Derived Metabolites and Chronic Kidney Disease: The Forest (F)or the Trees?

Vanholder R, Glorieux G.

Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1311-1313. doi: 10.2215/CJN.08200718. Epub 2018 Aug 7. No abstract available.

PMID:
30087101
8.

Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).

Vanholder R, Van Laecke S, Glorieux G, Verbeke F, Castillo-Rodriguez E, Ortiz A.

Toxins (Basel). 2018 Jun 12;10(6). pii: E237. doi: 10.3390/toxins10060237. Review.

9.

Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate.

Gil RB, Ortiz A, Sanchez-Niño MD, Markoska K, Schepers E, Vanholder R, Glorieux G, Schmitt-Kopplin P, Heinzmann SS.

Nephrol Dial Transplant. 2018 Dec 1;33(12):2156-2164. doi: 10.1093/ndt/gfy020.

PMID:
29554320
10.

A plea for more uremic toxin research in children with chronic kidney disease.

Snauwaert E, Van Biesen W, Raes A, Glorieux G, Vanholder R, Vande Walle J, Eloot S.

Pediatr Nephrol. 2018 Jun;33(6):921-924. doi: 10.1007/s00467-018-3920-8. Epub 2018 Mar 2. No abstract available.

PMID:
29500629
11.

Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.

Vanholder R, Pletinck A, Schepers E, Glorieux G.

Toxins (Basel). 2018 Jan 8;10(1). pii: E33. doi: 10.3390/toxins10010033. Review.

12.

Assessment of the association between increasing membrane pore size and endotoxin permeability using a novel experimental dialysis simulation set-up.

Schepers E, Glorieux G, Eloot S, Hulko M, Boschetti-de-Fierro A, Beck W, Krause B, Van Biesen W.

BMC Nephrol. 2018 Jan 5;19(1):1. doi: 10.1186/s12882-017-0808-y.

13.

p-cresol sulfate and indoxyl sulfate: some clouds are gathering in the uremic toxin sky.

Evenepoel P, Glorieux G, Meijers B.

Kidney Int. 2017 Dec;92(6):1323-1324. doi: 10.1016/j.kint.2017.06.029.

PMID:
29153138
14.

Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker.

Pontillo C, Zhang ZY, Schanstra JP, Jacobs L, Zürbig P, Thijs L, Ramírez-Torres A, Heerspink HJL, Lindhardt M, Klein R, Orchard T, Porta M, Bilous RW, Charturvedi N, Rossing P, Vlahou A, Schepers E, Glorieux G, Mullen W, Delles C, Verhamme P, Vanholder R, Staessen JA, Mischak H, Jankowski J.

Kidney Int Rep. 2017 Nov;2(6):1066-1075. doi: 10.1016/j.ekir.2017.06.004.

15.

Spontaneous variability of pre-dialysis concentrations of uremic toxins over time in stable hemodialysis patients.

Eloot S, Van Biesen W, Roels S, Delrue W, Schepers E, Dhondt A, Vanholder R, Glorieux G.

PLoS One. 2017 Oct 10;12(10):e0186010. doi: 10.1371/journal.pone.0186010. eCollection 2017.

16.

Concentrations of representative uraemic toxins in a healthy versus non-dialysis chronic kidney disease paediatric population.

Snauwaert E, Van Biesen W, Raes A, Glorieux G, Van Bogaert V, Van Hoeck K, Coppens M, Roels S, Vande Walle J, Eloot S.

Nephrol Dial Transplant. 2018 Jun 1;33(6):978-986. doi: 10.1093/ndt/gfx224.

PMID:
28992139
17.

p-Cresyl glucuronide is a major metabolite of p-cresol in mouse: in contrast to p-cresyl sulphate, p-cresyl glucuronide fails to promote insulin resistance.

Koppe L, Alix PM, Croze ML, Chambert S, Vanholder R, Glorieux G, Fouque D, Soulage CO.

Nephrol Dial Transplant. 2017 Dec 1;32(12):2000-2009. doi: 10.1093/ndt/gfx089.

PMID:
28992089
18.

Binding of bromocresol green and bromocresol purple to albumin in hemodialysis patients.

Delanghe S, Biesen WV, Velde NV, Eloot S, Pletinck A, Schepers E, Glorieux G, Delanghe JR, Speeckaert MM.

Clin Chem Lab Med. 2018 Feb 23;56(3):436-440. doi: 10.1515/cclm-2017-0444.

PMID:
28985181
19.

Accumulation of uraemic toxins is reflected only partially by estimated GFR in paediatric patients with chronic kidney disease.

Snauwaert E, Van Biesen W, Raes A, Holvoet E, Glorieux G, Van Hoeck K, Van Dyck M, Godefroid N, Vanholder R, Roels S, Walle JV, Eloot S.

Pediatr Nephrol. 2018 Feb;33(2):315-323. doi: 10.1007/s00467-017-3802-5. Epub 2017 Sep 22.

PMID:
28939943
20.

The Place of Large Pore Membranes in the Treatment Portfolio of Patients on Hemodialysis.

Van Biesen W, Vanholder R, Schepers E, Glorieux G, Dhondt A, Eloot S.

Contrib Nephrol. 2017;191:168-177. doi: 10.1159/000479265. Epub 2017 Sep 14. Review.

PMID:
28910800

Supplemental Content

Loading ...
Support Center